Referências
Principais artigos
Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice puidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021 Jan 23;72(1):e1-48.Texto completo Resumo
Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - Lyme disease. May 2023 [internet publication].Texto completo
Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of lyme disease. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):703.Texto completo Resumo
National Institute for Health and Care Excellence (UK). Lyme disease. October 2018 [internet publication].Texto completo
Mygland A, Ljøstad U, Fingerle V, et al; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010 Jan;17(1):8-16;e1-4.Texto completo Resumo
American Academy of Pediatrics. Lyme disease. In: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 515-23.
Artigos de referência
1. Kullberg BJ, Vrijmoeth HD, van de Schoor F, et al. Lyme borreliosis: diagnosis and management. BMJ. 2020 May 26;369:m1041.Texto completo Resumo
2. Tibbles CD, Edlow JA. Does this patient have erythema migrans? JAMA. 2007 Jun 20;297(23):2617-27. Resumo
3. Marques AR, Strle F, Wormser GP. Comparison of Lyme Disease in the United States and Europe. Emerg Infect Dis. 2021 Aug;27(8):2017-24.Texto completo Resumo
4. Ogrinc K, Lusa L, Lotrič-Furlan S, et al. Course and outcome of early European Lyme Neuroborreliosis (Bannwarth Syndrome): clinical and laboratory findings. Clin Infect Dis. 2016 Aug 1;63(3):346-53.Texto completo Resumo
5. Nau R, Christen HJ, Eiffert H. Lyme disease: current state of knowledge. Dtsch Arztebl Int. 2009 Jan;106(5):72-81;quiz 82, I.Texto completo Resumo
6. Schwartz AM, Hinckley AF, Mead PS, et al. Surveillance for Lyme disease - United States, 2008-2015. MMWR Surveill Summ. 2017 Nov 10;66(22):1-12.Texto completo Resumo
7. World Health Organization. Lyme borreliosis in Europe: influences of climate and climate change epidemiology, ecology and adaptation measures. Sep 2006 [internet publication].Texto completo
8. Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europe†. J Public Health (Oxf). 2017 Mar 1;39(1):74-81.Texto completo Resumo
9. Burn L, Vyse A, Pilz A, et al. Incidence of Lyme Borreliosis in Europe: a systematic review (2005-2020). Vector Borne Zoonotic Dis. 2023 Apr;23(4):172-94.Texto completo Resumo
10. Centers for Disease Control and Prevention. Lyme Disease-Data and Surveillance. Aug 2022 [internet publication].Texto completo
11. Kugeler KJ, Schwartz AM, Delorey MJ, et al. Estimating the frequency of lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021 Feb;27(2):616-19.Texto completo Resumo
12. Rosenberg R, Lindsey NP, Fischer M, et al. Vital signs: trends in reported vectorborne disease cases - United States and Territories, 2004-2016. MMWR Morb Mortal Wkly Rep. 2018 May 4;67(17):496-501.Texto completo Resumo
13. Thomson MC, Stanberry LR. Climate change and vectorborne diseases. N Engl J Med. 2022 Nov 24;387(21):1969-78.Texto completo Resumo
14. Steere AC, McHugh G, Suarez C, et al. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis. 2003 Apr 15;36(8):1078-81.Texto completo Resumo
15. Pritt BS, Mead PS, Johnson DK, et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. Lancet Infect Dis. 2016 May;16(5):556-64.Texto completo Resumo
16. Wormser GP. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease. Diagn Microbiol Infect Dis. 2022 Jan;102(1):115572.Texto completo Resumo
17. McVicar M, Rivera I, Reyes JB, et al. Ecology of Ixodes pacificus ticks and associated pathogens in the Western United States. Pathogens. 2022 Jan 13;11(1).Texto completo Resumo
18. Singh SK, Girschick HJ. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004;10:598-614. Resumo
19. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004 Apr;113(8):1093-101.Texto completo Resumo
20. Halsey SJ, Allan BF, Miller JR. The role of Ixodes scapularis, Borrelia burgdorferi and wildlife hosts in Lyme disease prevalence: a quantitative review. Ticks Tick Borne Dis. 2018 Jul;9(5):1103-14.Texto completo Resumo
21. Oliver JD, Bennett SW, Beati L, et al. Range expansion and increasing Borrelia burgdorferi Infection of the Tick Ixodes scapularis (Acari: Ixodidae) in Iowa, 1990-2013. J Med Entomol. 2017 Nov 7;54(6):1727-34.Texto completo Resumo
22. Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med. 2003 Jun 12;348(24):2424-30. Resumo
23. Daltroy LH, Phillips C, Lew R, et al. A controlled trial of a novel primary prevention program for Lyme disease and other tick-borne illnesses. Health Educ Behav. 2007 Jun;34(3):531-42. Resumo
24. Bratton RL, Whiteside JW, Hovan MJ, et al. Diagnosis and treatment of Lyme disease. Mayo Clin Proc. 2008 May;83(5):566-71.Texto completo Resumo
25. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice puidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021 Jan 23;72(1):e1-48.Texto completo Resumo
26. Razai MS, Doerholt K, Galiza E, et al. Tick bite. BMJ. 2020 Aug 13;370:m3029.Texto completo Resumo
27. Dessau RB, van Dam AP, Fingerle V, et al. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis. Clin Microbiol Infect. 2018 Feb;24(2):118-24.Texto completo Resumo
28. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - Lyme disease. May 2023 [internet publication].Texto completo
29. Centers for Disease Control and Prevention. Lyme disease-signs and symptoms of untreated Lyme Disease. Jan 2021 [internet publication].Texto completo
30. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995 Aug 11;44(31):590-1.Texto completo Resumo
31. Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of lyme disease. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):703.Texto completo Resumo
32. National Institute for Health and Care Excellence (UK). Lyme disease. October 2018 [internet publication].Texto completo
33. Mygland A, Ljøstad U, Fingerle V, et al; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010 Jan;17(1):8-16;e1-4.Texto completo Resumo
34. Moore A, Nelson C, Molins C, et al. Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. Emerg Infect Dis. 2016 Jul;22(7):1169–77.Texto completo Resumo
35. Branda JA, Steere AC. Laboratory diagnosis of Lyme borreliosis. Clin Microbiol Rev. 2021 Jan 27 [Epub ahead of print]. Resumo
36. Aguero-Rosenfeld ME, Wang G, Schwartz I, et al. Diagnosis of Lyme borreliosis. Clin Microbiol Rev. 2005 Jul;18(3):484-509.Texto completo Resumo
37. American Academy of Pediatrics. Lyme disease. In: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 515-23.
38. American Academy of Pediatrics. Tetracyclines. In: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 905-6.
39. Steere AC, Malawista SE, Newman JH, et al. Antibiotic therapy in Lyme disease. Ann Intern Med. 1980 Jul;93(1):1-8. Resumo
40. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of early manifestations of Lyme disease. Ann Intern Med. 1983 Jul;99(1):22-6. Resumo
41. Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396-403. Resumo
42. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992 Aug 15;117(4):273-80. Resumo
43. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995 Mar;39(3):661-7.Texto completo Resumo
44. Nowakowski J, Nadelman RB, Forseter G, et al. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):223-7. Resumo
45. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics. 2002 Jun;109(6):1173-7. Resumo
46. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 May 6;138(9):697-704. Resumo
47. Stupica D, Collinet-Adler S, Blagus R, et al. Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial. Lancet Infect Dis. 2023 Mar;23(3):371-9.Texto completo Resumo
48. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 1996 May 1;124(9):785-91.Texto completo Resumo
49. Berende A, Ter Hofstede HJM, Vos FJ, et al. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. Neurology. 2019 Mar 26;92(13):e1447-55.Texto completo Resumo
50. Waddell LA, Greig J, Lindsay LR, et al. A systematic review on the impact of gestational Lyme disease in humans on the fetus and newborn. PLoS One. 2018 Nov 12;13(11):e0207067.Texto completo Resumo
51. Nadelman RB, Nowakowski J, Fish D, et al; Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001 Jul 12;345(2):79-84.Texto completo Resumo
52. Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum. 1994 Jun;37(6):878-88. Resumo
53. Eckman MH, Steere AC, Kalish RA, et al. Cost effectiveness of oral as compared with intravenous antibiotic treatment for patients with early Lyme disease or Lyme arthritis. N Engl J Med. 1997 Jul 31;337(5):357-63.Texto completo Resumo
54. Torbahn G, Hofmann H, Rücker G, et al. Efficacy and safety of antibiotic therapy in early cutaneous lyme borreliosis: a network meta-analysis. JAMA Dermatol. 2018 Nov 1;154(11):1292-1303.Texto completo Resumo
55. Cardenas-de la Garza JA, De la Cruz-Valadez E, Ocampo-Candiani J, et al. Clinical spectrum of Lyme disease. Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):201-8.Texto completo Resumo
56. Nemeth J, Bernasconi E, Heininger U, et al. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016 Dec 5;146:w14353.Texto completo Resumo
57. Eliassen KE, Hjetland R, Reiso H, et al. Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. Scand J Prim Health Care. 2017 Mar;35(1):75-83.Texto completo Resumo
58. Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374:1209-1220.Texto completo Resumo
59. Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin North Am. 2015 Jun;29(2):309-23.Texto completo Resumo
60. Mead P. Epidemiology of Lyme Disease. Infect Dis Clin North Am. 2022 Sep;36(3):495-521.Texto completo Resumo
61. Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol. 2004 Feb;4(2):143-52.Texto completo Resumo
62. Koedel U, Fingerle V, Pfister HW. Lyme neuroborreliosis-epidemiology, diagnosis and management. Nat Rev Neurol. 2015 Aug;11(8):446-56.Texto completo Resumo
63. Asbrink E, Hovmark A, Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Dec;263(1-2):253-61.Texto completo Resumo
64. Dattwyler RJ, Halperin JJ, Volkman DJ, et al. Treatment of late Lyme borreliosis - randomized comparison of ceftriaxone and penicillin. Lancet. 1988 May 28;1(8596):1191-4. Resumo
65. Dattwyler RJ, Wormser GP, Rush TJ, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr. 2005 Jun;117(11-12):393-7. Resumo
66. Scheffold N, Herkommer B, Kandolf R, et al. Lyme carditis--diagnosis, treatment and prognosis. Dtsch Arztebl Int. 2015 Mar 20;112(12):202-8.Texto completo Resumo
67. Marzec NS, Nelson C, Waldron PR, et al. Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):607-9.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal